YZYu Zhou

Yu Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu Zhou has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Herrmann

    DWI – Leibniz Institute for Interactive Materials, Aachen, Germany

    5 shared publications
  • Robert Göstl

    Department of Chemistry and Biology University of Wuppertal Wuppertal Germany

    4 shared publications
  • Shuaidong Huo

    Xiamen University

    4 shared publications
  • Hua Lu

    Peking University

    3 shared publications
  • Jingsong Yuan

    Beijing National Laboratory for Molecular Sciences, Center for Soft Matter Science and Engineering, Key Laboratory of Polymer Chemistry and Physics of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, People's Republic of China

    3 shared publications
  • Yingqin Hou

    Beijing National Laboratory for Molecular Sciences, Center for Soft Matter Science and Engineering, Key Laboratory of Polymer Chemistry and Physics of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, People's Republic of China

    3 shared publications

Latest Publications

  • Ultrasonic nanoreactors: porous nanomaterials as multimodal platforms for precision ultrasound-responsive therapy and sonotherapy in nanomedicine

    by Zepu Chang, Jinpu Yang, Shuaidong Huo, Yu Zhou, Pengkun Zhao

    This review highlights recent advances in porous nanomaterials as ultrasonic nanoreactors for ultrasound-responsive therapy and sonotherapy, covering their synthesis, mechanisms, and applications.


  • Supramolecular adhesive materials based on urea assembly

    by Jialin Jian, Yu Zhou, Jiaqi Su, Zhenhua Gao, Shuangying Wei, Shuaiyuan Han


  • Open Access

    Supplementary Figures 3 and 4 from Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5

    by Marianne Le Gall, Ronan Crépin, Madeline Neiveyans, Christian Auclair, Yongfeng Fan, Yu Zhou, James D. Marks, André Pèlegrin, Marie-Alix Poul

  • Open Access

    Fracture Detection in Bio‐Glues with Fluorescent‐Protein‐Based Optical Force Probes

    by Yu Zhou, Silvia P. Centeno, Kuan Zhang, Lifei Zheng, Robert Göstl, Andreas Herrmann

    Glues are being used to bond, seal, and repair in industry and biomedicine. The improvement of gluing performance is hence important for the development of new glues with better and balanced property spaces, which in turn necessitates a mechanistic understanding of their mechanical failure. Optical force probes (OFPs) allow the observation of mechanical material damage in polymers from the macro‐ down to the microscale, yet have never been employed in glues. Here, the development of a series of ratiometric OFPs based on fluorescent‐protein–dye and protein–protein conjugates and their incorporation into genetically engineered bio‐glues is reported. The OFPs are designed to efficiently modulate Förster resonance energy transfer upon force application thereby reporting on force‐induced molecular alterations independent of concentration and fluorescence intensity both spectrally and through their fluorescence lifetime. By fluorescence spectroscopy in solution and in the solid state and by fluorescence lifetime imaging microscopy, stress concentrations are visualized and adhesive and cohesive failure in the fracture zone is differentiated.


  • Reversible regulation of metallo-base-pair interactions for DNA dehybridization by ultrasound

    by Shuaidong Huo, Yu Zhou, Zhihuan Liao, Pengkun Zhao, Miancheng Zou, Robert Göstl, Andreas Herrmann

    Ultrasound leads to the reversible dissociation of DNA metallo-base-pairs when these motifs are functionalized with oligodeoxynucleotide sequences of sufficient length.


  • Open Access

    Kontrolle über die optische und katalytische Aktivität gentechnisch hergestellter Proteine mit Ultraschall

    by Yu Zhou, Shuaidong Huo, Mark Loznik, Robert Göstl, Arnold J. Boersma, Andreas Herrmann

    Ultraschall (US) erzeugt mittels Kavitation mechanische Kräfte, die Polymerketten in Lösung dehnen und brechen. Diese Art der Polymer‐Mechanochemie wird für synthetische Polymere, nicht aber für Biomakromoleküle verwendet, obwohl US biokompatibel ist und gemeinhin für die medizinische Therapie sowie für die Bildgebung in vivo eingesetzt wird. Die Möglichkeit, die Aktivität von Proteinen durch US zu kontrollieren, wäre daher ein wichtiger Meilenstein für diese Disziplinen. Hier zeigen wir die ersten Beispiele für die selektive Aktivierung und Deaktivierung von Proteinen durch US. Mit der Verwendung von GFP als Modellsystem zeigen wir modellhaft, wie Proteine mit US‐Empfindlichkeit ausgestattet werden können. Der Einbau von langen und hochgeladenen Domänen ermöglicht eine effiziente Kraftübertragung auf die Proteinstruktur. Dieses Prinzip nutzen wir dann, um die katalytische Aktivität von Trypsin zu aktivieren, indem wir die Freisetzung seines Inhibitors auslösen. Wir erwarten, dass das Konzept des Ein‐ und Ausschaltens der Proteinaktivität durch US als Bauplan für die Fernsteuerung anderer bioaktiver Moleküle dienen wird.


  • Open Access

    Controlling Optical and Catalytic Activity of Genetically Engineered Proteins by Ultrasound

    by Yu Zhou, Shuaidong Huo, Mark Loznik, Robert Göstl, Arnold J. Boersma, Andreas Herrmann

    Ultrasound (US) produces cavitation‐induced mechanical forces stretching and breaking polymer chains in solution. This type of polymer mechanochemistry is widely used for synthetic polymers, but not biomacromolecules, even though US is biocompatible and commonly used for medical therapy as well as in vivo imaging. The ability to control protein activity by US would thus be a major stepping‐stone for these disciplines. Here, we provide the first examples of selective protein activation and deactivation by means of US. Using GFP as a model system, we engineer US sensitivity into proteins by design. The incorporation of long and highly charged domains enables the efficient transfer of force to the protein structure. We then use this principle to activate the catalytic activity of trypsin by inducing the release of its inhibitor. We expect that this concept to switch “on” and “off” protein activity by US will serve as a blueprint to remotely control other bioactive molecules.


  • Open Access

    De novo rational design of a freestanding, supercharged polypeptide, proton-conducting membrane

    by Chao Ma, Jingjin Dong, Marco Viviani, Isotta Tulini, Nicola Pontillo, Sourav Maity, Yu Zhou, Wouter H. Roos, Kai Liu, Andreas Herrmann, et al.

    Innovative bio-inspired device based on supercharged spider silk nanostructures engineered to efficiently transport protons.


  • Open Access

    Therapeutic Protein PEPylation: The Helix of Nonfouling Synthetic Polypeptides Minimizes Antidrug Antibody Generation

    by Yingqin Hou, Yu Zhou, Hao Wang, Jialing Sun, Ruijue Wang, Kai Sheng, Jingsong Yuan, Yali Hu, Yu Chao, Zhuang Liu, et al.

    Polymer conjugation is a clinically proven approach to generate long acting protein drugs with decreased immune responses. Although poly(ethylene glycol) (PEG) is one of the most commonly used conjugation partners due to its unstructured conformation, its therapeutic application is limited by its poor biodegradability, propensity to induce an anti-PEG immune response, and the resultant accelerated blood clearance (ABC) effect. Moreover, the prevailing preference of unstructured polymers for protein conjugation still lacks strong animal data support with appropriate control reagents. By using two biodegradable synthetic polypeptides with similar structural compositions (l-P(EG3Glu) and dl-P(EG3Glu)) for site-specific protein modification, in the current study, we systematically investigate the effect of the polymer conformation on the in vivo pharmacological performances of the resulting conjugates. Our results reveal that the conjugate l20K-IFN, interferon (IFN) modified with the helical polypeptide l-P(EG3Glu) shows improved binding affinity, in vitro antiproliferative activity, and in vivo efficacy compared to those modified with the unstructured polypeptide analogue dl-P(EG3Glu) or PEG. Moreover, l20K-IFN triggered significantly less antidrug and antipolymer antibodies than the other two. Importantly, the unusual findings observed in the IFN series are reproduced in a human growth hormone (GH) conjugate series. Subcutaneously infused l20K-GH, GH modified with l-P(EG3Glu), evokes considerably less anti-GH and antipolymer antibodies compared to those modified with dl-P(EG3Glu) or PEG (dl20K-GH or PEG20K-GH). As a result, repeated injections of dl20K-GH or PEG20K-GH, but not l20K-GH, result in a clear ABC effect and significantly diminished drug availability in the blood. Meanwhile, immature mouse bone marrow cells incubated with the helical l20K-GH exhibit decreased drug uptake and secretion of proinflammatory cytokines compared to those treated with one of the other two GH conjugates bearing unstructured polymers. Taken together, the current study highlights an urgent necessity to systematically reassess the pros and cons of choosing unstructured polymers for protein conjugation. Furthermore, our results also lay the foundation for the development of next-generation biohybrid drugs based on helical synthetic polypeptides.


  • Macrocyclization of Interferon–Poly(α-amino acid) Conjugates Significantly Improves the Tumor Retention, Penetration, and Antitumor Efficacy

    by Yingqin Hou, Yu Zhou, Hao Wang, Ruijue Wang, Jingsong Yuan, Yali Hu, Kai Sheng, Juan Feng, Shengtao Yang, Hua Lu

    Cyclization and polymer conjugation are two commonly used approaches for enhancing the pharmacological properties of protein drugs. However, cyclization of parental proteins often only affords a modest improvement in biochemical or cell-based in vitro assays. Moreover, very few studies have included a systematic pharmacological evaluation of cyclized protein-based therapeutics in live animals. On the other hand, polymer-conjugated proteins have longer circulation half-lives but usually show poor tumor penetration and suboptimal pharmacodynamics due to increased steric hindrance. We herein report the generation of a head-to-tail interferon–poly(α-amino acid) macrocycle conjugate circ-P(EG3Glu)20-IFN by combining the aforementioned two approaches. We then compared the antitumor pharmacological activity of this macrocycle conjugate against its linear counterparts, N-P(EG3Glu)20-IFN, C-IFN-P(EG3Glu)20, and C-IFN-PEG. Our results found circ-P(EG3Glu)20-IFN to show considerably greater stability, binding affinity, and in vitro antiproliferative activity toward OVCAR3 cells than the three linear conjugates. More importantly, circ-P(EG3Glu)20-IFN exhibited longer circulation half-life, remarkably higher tumor retention, and deeper tumor penetration in vivo. As a result, administration of the macrocyclic conjugate could effectively inhibit tumor progression and extend survival in mice bearing established xenograft human OVCAR3 or SKOV3 tumors without causing severe paraneoplastic syndromes. Taken together, our study provided until now the most relevant experimental evidence in strong support of the in vivo benefit of macrocyclization of protein–polymer conjugates and for its application in next-generation therapeutics.